Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A. Visani G, et al. Among authors: caballero md. Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3. Blood. 2011. PMID: 21816830 Free article. Clinical Trial.
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.
Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Gonella R, Gobbi M, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Loscocco F, Isidori A. Visani G, et al. Among authors: caballero md. Blood. 2014 Nov 6;124(19):3029-31. doi: 10.1182/blood-2014-08-596668. Blood. 2014. PMID: 25377565 Free article. Clinical Trial. No abstract available.
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
Martino R, Caballero MD, Pérez-Simón JA, Canals C, Solano C, Urbano-Ispízua A, Bargay J, Léon A, Sarrá J, Sanz GF, Moraleda JM, Brunet S, San Miguel J, Sierra J; AML and alloPBSCT Subcommittees of the Spanish Group for Hematopoietic Transplantation. Martino R, et al. Among authors: caballero md. Blood. 2002 Sep 15;100(6):2243-5. doi: 10.1182/blood-2002-02-0400. Blood. 2002. PMID: 12200391 Free article. Clinical Trial.
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J. Alvarez I, et al. Among authors: caballero md. Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83. doi: 10.1016/j.bbmt.2005.09.009. Biol Blood Marrow Transplant. 2006. PMID: 16443515 Free article. Clinical Trial.
HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.
Alcoceba M, Sebastián E, Marín L, Balanzategui A, Sarasquete ME, Chillón MC, Jiménez C, Puig N, Corral R, Pardal E, Grande C, Bello JL, Albo C, de la Cruz F, Panizo C, Martín A, González-Barca E, Caballero MD, San Miguel JF, García-Sanz R, González M. Alcoceba M, et al. Among authors: caballero md. Blood. 2013 Aug 22;122(8):1448-54. doi: 10.1182/blood-2013-02-483420. Epub 2013 Jul 10. Blood. 2013. PMID: 23843497 Free article.
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group). Martín A, et al. Among authors: caballero md. Haematologica. 2008 Dec;93(12):1829-36. doi: 10.3324/haematol.13440. Epub 2008 Oct 22. Haematologica. 2008. PMID: 18945747 Free article.
Genetic complexity impacts the clinical outcome of follicular lymphoma patients.
García-Álvarez M, Alonso-Álvarez S, Prieto-Conde I, Jiménez C, Sarasquete ME, Chillón MC, Medina A, Balanzategui A, Maldonado R, Antón A, Rodríguez M, Blanco O, Díaz LG, Tamayo P, Blanco P, Esteban C, González-Calle V, Puig N, Gutiérrez N, Martín A, García-Sanz R, González M, Caballero MD, Alcoceba M. García-Álvarez M, et al. Among authors: caballero md. Blood Cancer J. 2021 Jan 11;11(1):11. doi: 10.1038/s41408-020-00395-y. Blood Cancer J. 2021. PMID: 33431798 Free PMC article. No abstract available.
ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Labrador J, Cabrero-Calvo M, Pérez-López E, Mateos MV, Vázquez L, Caballero MD, García-Sanz R. Labrador J, et al. Among authors: caballero md. Ann Hematol. 2014 Oct;93(10):1745-53. doi: 10.1007/s00277-014-2114-0. Epub 2014 May 27. Ann Hematol. 2014. PMID: 24863692
Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.
Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD; 'Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea' (GEL-TAMO). Rodríguez J, et al. Among authors: caballero md. Eur J Haematol. 2007 Jul;79(1):32-8. doi: 10.1111/j.1600-0609.2007.00856.x. Eur J Haematol. 2007. PMID: 17598836 Clinical Trial.
Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas.
García-Álvarez M, Alonso-Álvarez S, Prieto-Conde I, Jiménez C, Sarasquete ME, Chillón MC, Medina A, Balanzategui A, Maldonado R, Antón A, Puig N, Rodríguez M, Blanco O, Tamayo P, González-Calle V, Martín A, García-Sanz R, González M, Caballero MD, Alcoceba M. García-Álvarez M, et al. Among authors: caballero md. Blood Cancer J. 2019 Jun 17;9(7):52. doi: 10.1038/s41408-019-0213-9. Blood Cancer J. 2019. PMID: 31209206 Free PMC article.
153 results